News | December 17, 2024
Merck to acquire HUB Organoids to advance cell culture portfolio
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Harnessing advanced data analysis for early detection, prevention and better outcomes
Final decision from the European Commission is anticipated within the coming months
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
First and only PARP inhibitor to improve overall survival in early breast cancer
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
Aims to become India’s leading cancer testing company
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Subscribe To Our Newsletter & Stay Updated
